Advances in Interventional Cardiology
eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current Issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

In-hospital prognosis of high bleeding risk patients with an acute coronary syndrome and successful percutaneous coronary intervention: a single-center real-world registry

Charalampos Kakderis
1
,
Matthaios Didagelos
1
,
Thomas Zegkos
1
,
Konstantinos C. Theodoropoulos
1
,
Antonios Kouparanis
1
,
Dimitra Ioakeimidou
1
,
Anna Iliou
1
,
George Kassimis
2
,
Stergios Tzikas
3
,
Antonios Ziakas
1

  1. First Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Greece
  2. Second Cardiology Department, Hippokration University Hospital, Aristotle University of Thessaloniki, Greece
  3. Third Cardiology Department, Hippokration University Hospital, Aristotle University of Thessaloniki, Greece
Adv Interv Cardiol
DOI: https://doi.org/10.5114/aic.2025.156886
Online publish date: 2025/12/10
Article file
- In-hospital prognosis.pdf  [0.44 MB]
Get citation
 
 
1. Lee YJ, Suh Y, Kim JS, et al. Ticagrelor monotherapy after 3-month dual antiplatelet therapy in acute coronary syndrome by high bleeding risk: the subanalysis from the TICO Trial. Korean Circ J 2022; 52: 324-37.
2. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS Trial. JACC Cardiovasc Interv 2016; 9: 426-36.
3. Motovska Z, Montalescot G. The Cornelian dilemma of quitting DAPT. Eur Heart J 2021; 42: 4635-7.
4. Kim MC, Ahn SG, Cho KH, et al. De-escalation from ticagrelor to clopidogrel in patients with acute myocardial infarction: the TALOS-AMI HBR substudy. EuroIntervention 2023; 19: E832-43.
5. Ueki Y, Bär S, Losdat S, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention 2020; 16: 371-9.
6. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-69.
7. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44: 3720-826.
8. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140: 240-61.
9. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011; 123: 2736-47.
10. Cao D, Mehran R, Dangas G, et al. Validation of the Academic Research Consortium high bleeding risk definition in contemporary PCI patients. J Am Coll Cardiol 2020; 75: 2711-22.
11. Abu-Assi E, Raposeiras-Roubín S, Cespón Fernández M, et al. Applicability of the Academic Research Consortium for High Bleeding Risk in acute coronary syndrome undergoing percutaneous coronary intervention. Rev Esp Cardiol 2022; 75: 375-83.
12. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 2021; 385: 1643-55.
13. Mehran R, Cao D, Angiolillo DJ, et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc Interv 2021; 14: 1870-83.
14. Pivato CA, Reimers B, Testa L, et al. One-month dual antiplatelet therapy after bioresorbable polymer everolimus-eluting stents in high bleeding risk patients. J Am Heart Assoc 2022; 11: e023454.
15. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med 2020; 382: 1208-18.
16. Zocca P, Kok MM, van der Heijden LC, et al. High bleeding risk patients treated with very thin-strut biodegradable polymer or thin-strut durable polymer drug-eluting stents in the BIO-RESORT trial. Cardiovasc Drugs Ther 2018; 32: 567-76.
17. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025-34.
18. Mehran R, Nikolsky E, Lansky AJ, et al. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies. An ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Substudy. JACC Cardiovasc Interv 2009; 2: 748-57.
19. Saltzman AJ, Stone GW, Claessen BE, et al. Long-term impact of chronic kidney disease in patients with st-segment elevation myocardial infarction treated with primary percutaneous coronary intervention the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. JACC Vardiovasac Interv 2011; 4: 1011-9.
20. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-st-segment- elevation myocardial infarction the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) bleeding score. Circulation 2009; 119: 1873-82.
21. Yamamoto K, Natsuaki M, Morimoto T, et al. Transradial vs. transfemoral percutaneous coronary intervention in patients with or without high bleeding risk criteria. Circ J 2020; 84: 723-32.
22. Landi A, Heg D, Frigoli E, et al. Abbreviated or standard antiplatelet therapy in HBR patients: final 15-month results of the MASTER-DAPT trial. JACC Cardiovasc Interv 2023; 16: 798-812.
23. Capodanno D, Greco A. Dual antiplatelet therapy in patients at high bleeding risk: less is more - more or less. Eur Heart J 2023; 44: 969-71.
24. Smits PC, Frigoli E, Vranckx P, et al. Abbreviated atiplatelet therapy after coronary stenting in patients with myocardial infarction at high bleeding risk. J Am Coll Cardiol 2022; 80: 1220-37.
25. Valgimigli M, Cao D, Angiolillo DJ, et al. Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI. J Am Coll Cardiol 2021; 78: 2060-72.
26. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 2020; 395: 1374-81.
27. Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDEHEART Registry. Circulation 2020; 142: 1700-8.
28. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5: 680-8.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.